Diagnostic Innovation Reimagined
Our mission is to explore and embrace groundbreaking biotechnologies, propelling new frontiers of next generation sequencing diagnostics.
Our mission is to explore and embrace groundbreaking biotechnologies, propelling new frontiers of next generation sequencing diagnostics.
Our vision is to create a synergistic ecosystem of disruptive diagnostic solutions that accelerates research, development, and commercialization to enhance clinical care and patient outcomes.
At the core of Renew’s innovation lies our NESSI-Seq platform, powered by Nanohyb. NESSI-Seq utilizes advanced native DNA sequencing 3.0 technology and proprietary protocols that enhance sensitivity and specificity while reducing costs.
We have created a dynamic innovation ecosystem through strategic sponsored research agreements (SRAs) with R&D laboratories to explore novel applications of NESSI-Seq and unlock new clinical applications and market opportunities.
To achieve these ambitious goals, we have built a NGS R&D laboratory and are constructing a 20,000 square foot, high-throughput, clinical lab capable of processing over 3 million samples per year.
We will continue innovating and nurturing strong, lasting relationships with commercial partners, healthcare organizations, patients, and biotech professionals to tackle the biggest challenges in healthcare.
Our scientific and strategic leaders explore the advantages of the NESSI-Seq platform within the current diagnostic landscape to identify impactful opportunities.
Upon identifying a target market or research area, our team of scientists innovates, experiments, and develops novel assays to address clinical needs.
After validating the feasibility of the assays, our science team collaborates with our commercial team to refine protocols for market needs.
With optimized protocols, our clinical compliance experts navigate the regulatory landscape for release of the tests to physicians and patients.
Following regulatory approval, we seek strategic partners and clients to expand access and maximize the impact of the technologies on patients’ lives.
Neurodegenerative diseases (NGDs) affect millions worldwide. Resonant is developing tests to detect early biomarkers of neurodegeneration in diseases including Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS.)
These advancements are positioned to provide researchers, clinicians, and patients with accessible tools to diagnose, treat, and manage NGDs. Resonant is currently conducting a large-scale clinical validation study summer 2024 to verify the technology at scale.
